StageZero Life Sciences Ltd. — Interim / Quarterly Report 2024

Sep 30, 2024

StageZero Life Sciences Ltd.

Six-month periods ended June 30, 2024 and 2023

Unaudited, condensed consolidated interim financial statements and associated notes

[Expressed in US dollars, unless otherwise noted]

1

StageZero Life Sciences Ltd.

Unaudited Condensed Consolidated Interim Financial Statements

Six-month periods ended June 30, 2024 and 2023 [Expressed in US dollars, unless otherwise noted]

Consolidated Financial Statements

Consolidated Statements of Financial Position	3
Consolidated Statements of Loss and Comprehensive Loss	4
Consolidated Statements of Changes in Shareholders’ Equity (Deficiency)	5
Consolidated Statements of Cash Flows	6
Notes to the Consolidated Financial Statements	7-18

2

STAGEZERO LIFE SCIENCES LTD. CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION [EXPRESSED IN US DOLLARS]

	Notes	June 30, 2024	December 31, 2023
		$	$
ASSETS
Current
Cash		20,721	26,353
Trade and other receivables		138,819	88,594
Inventories	4	22,570	22,570
Short-termportion ofprepaid expenses and deposits		43,307	90,016
Total current assets		225,417	227,533
Non-current assets
Property, plant and equipment, net		151,920	214,008
Right of use assets		206,401	202,101
Total non-current assets		358,321	416,109
Total assets		583,738	643,642
LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIENCY)
Current
Trade and other payables	5	8,760,352	7,851,681
Deferred revenues	15	37,208	68,631
Short-term portion of lease liabilities		71,397	39,869
Fair value of convertible debenture	6[c]	-	54,950
Short-term loan	6[d]	367,239	428,925
Short-term liabilities		67,340	67,340
Short-term portion of warrant liability	7	-	181
Short-termportion of notespayable	6[a][b]	657,763	437,764
Total current liabilities		9,961,299	8,949,341
Non-current liabilities
Long-term portion of warrant liability	7	377,994	426,310
Long-term portion of lease liabilities		144,638	163,462
Long-term loan		44,544	44,544
Long-termportion of notespayable	6[b]	793,810	727,610
Total non-current liabilities		1,360,986	1,361,926
Total liabilities		11,322,285	10,311,267
Shareholders’ equity (deficiency)
Share capital	8[b]	101,906,557	101,906,557
Contributed surplus	8[d]	13,248,877	13,225,151
Accumulated other comprehensive income		1,234,743	1,248,663
Deficit		(127,128,724)	(126,047,996)
Total shareholders’ deficiency		(10,738,547)	(9,667,625)
Total liabilities and shareholders’ deficiency		583,738	643,642
Commitments and contingencies	17
Subsequent event	18

See accompanying notes to the consolidated financial statements.

Approved by the Company’s board of directors and authorized for issue on September 27, 2024:

(signed) James R. Howard-Tripp, Director

(signed) Garth MacRae, Director

3

STAGEZERO LIFE SCIENCES LTD. CONDENSED CONSOLIDATED INTERIM STATEMENTS OF LOSS AND COMPREHENSIVE LOSS [EXPRESSED IN US DOLLARS]

Notes	Three-month period ended June 30 Six-month period ended June 30
	2024 2023 2024 2023 $ $ $ $
REVENUES 19 Cost of revenue 11	390,083793,307912,0041,555,281 382,265671,752 677,7891,297,638
Grossprofit	7,818121,555234,215257,643
EXPENSES Research and development 11 Sales and marketing 11 General and administrative 11	-83,234 -144,244 -16,646-92,779 703,101842,4271,225,1032,096,575
Total Expenses	703,101 942,307 1,225,103 2,333,598
Loss from operations	(695,283) (820,752) (990,888) (2,075,955)
Loss (gain) from fair valuation of warrants 9 Change in fair value of convertible debenture 8[c] Finance and transaction costs 17	(98,491) (524,498) (48,497) (115,820) - 5,405- 13,583 52,66899,88093,418239,721
	(45,823) (419,213) 44,921137,484
Net loss before income taxes Current income taxes Deferred income taxes	(649,460) (401,539) (1,035,809) (2,213,439) - - - - - - - -
Net loss after income taxes Other comprehensive (loss) income: foreign translation adjustment Total loss and comprehensive loss for theyear	(649,460) (401,539) (1,035,809) (2,213,439) - - - - (649,460) (401,539) (1,035,809) (2,213,439)
Basic and diluted loss per common share 10	(0.00) (0.00) (0.01) (0.02)

See accompanying notes to the consolidated financial statements.

4

STAGEZERO LIFE SCIENCES LTD. CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY (DEFICIENCY) [EXPRESSED IN US DOLLARS]

	Share capital Contributed surplus Accumulated other comprehensive income Deficit Total
	Shares Amount # $ $ $ $ $
	[note 10[b]] [note 10]
Balance at January 1, 2024	123,532,948 101,906,557 13,225,151 1,248,663 (126,047,996) (9,667,625)
Net loss for the year	- - - - (1,035,809) (1,035,809)
Share-based compensation	- - 23,726 - - 23,726
Issuance of common shares in convertible debenture conversion	(58,840) (58,840)
Balance at June 30, 2024	123,532,948 101,906,557 13,248,877 1,189,823 (127,083,805) (10,738,547)
	Share capital Contributed surplus Accumulated other comprehensive income Deficit Total
	Shares Amount # $ $ $ $ $
	[note 10[b]] [note 10]
Balance at January 1, 2023	105,464,611 101,392,225 12,909,025 1,234,743 (123,039,330) (7,503,337)
Net loss for the year	- - - - (3,008,666) (3,008,666)
Share-based compensation	- - 316,126 - - 316,126
Issuance of common shares in capital commitment Issuance of option exercise Issuance of warrant exercise	4,711,226 159,801 159,801
	1,469,409 50,062 50,062
	215,354 10,593 10,593
Issuance of common shares in convertible debenture conversion	11,672,348 293,876 - 13,920 - 307,796
Balance at December 31, 2023	123,532,948 101,906,557 13,225,151 1,248,663 (126,047,996) (9,667,625)

See accompanying notes to the consolidated financial statements.

5

STAGEZERO LIFE SCIENCES LTD. CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS [EXPRESSED IN US DOLLARS]

Notes	Three-month period ended Six-month period ended June 30, 2024 June 30, 2023 June 30, 2024 June 30, 2023
OPERATING ACTIVITIES Net profit (loss) for the period Non-cash adjustments Share-based compensation 8[d] Depreciation 9 Change in right of use property Change in fair value of convertible debenture Non-cash interest expense Non-cash change in interest on lease liability Foreign exchange (Gain)/loss on revaluation of warrants
	(649,461) (401,539) (1,035,809) (2,213,439)
	-
	11,782 65,163 23,726 130,326
	43,811 59,576 62,088 119,152
	- 39,986 - 79,971
	- (3,673) - 4,505
	57,132 132,959 80,713 259,418
	12,705 4,007 12,705 10,251
	(145,979) 30,313 (166,529) (1,994)
	(1,497) (292,858) 48,497 115,820
Changes in non-cash working capital balances related to operations Trade and other receivables Contract Liability Prepaid expenses and deposits Inventory Trade and other payables	(671,507) (366,066) (974,609) (1,495,990)
	(42,559) 22,053 (50,225) (44,771)
	(51,058) (112,327) (31,423) (52,078)
	16,062 (118,339) 46,709 (101,869)
	- - - 12,678
	686,141 581,734 853,721 1,480,212
Cash used in operating activities	(62,921) 7,055 (155,827) (201,818)
FINANCING ACTIVITIES Short-term loan proceeds Payment of principal to Health Diagnostic Laboratories Inc. 6[a] Repayment of lease liability Repayment of short-term loan Proceeds from note payable Proceeds from stock option exercise Proceeds from issuance of shares and warrants for capital commitment Payment of note payable and interest
	- - 36,775 254,318
	- - - -
	(31,894) (68,324) (31,894) (135,975)
	- (227,621) - (227,621)
	110,000 - 210,000 50,000
	- 37,037 - 37,037
	- 279,764 - 279,764
	- (64,686) (7,183)
Cash provided by financing activities	78,106 20,856 150,195 250,340
INVESTING ACTIVITIES Net decrease in cash during the period Cash, beginning of period
	15,185 27,911 (5,632) 48,522
	5,536 36,295 26,353 15,684
Cash, end of period	20,721 64,206 20,721 64,206

See accompanying notes to the consolidated financial statements.

6

STAGEZERO LIFE SCIENCES LTD. NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE SIX-MONTH PERIOD ENDED June 30, 2024 AND 2023 [EXPRESSED IN US DOLLARS]

1. NATURE OF OPERATIONS AND GOING CONCERN

StageZero Life Sciences, Limited (“StageZero Life Sciences”, the “Company”, “we”, “us”, “our”) is a vertically integrated healthcare company at the nexus of three of the fastest growing and most exciting sectors of healthcare today; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. The Company is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention.

In its laboratory business the company continues to develop and commercialize proprietary molecular diagnostic tests for early detection of diseases and personalized health management, with a primary focus on cancer-related indications. The Company has developed a proprietary platform technology, the Sentinel Principle®, to identify novel biomarkers from whole blood. The Company’s lead product, Aristotle®, is a blood-based molecular diagnostic assessment that can detect an individual’s current risk for potentially having a variety of cancers.

The Company acquired the CareOncology businesses of Health Clinics Ltd, and Health Clinics USA Corp (“CareOncology”) in the third quarter of 2021 (Note 3). CareOncology operates virtual clinics as well as a physical clinic in the UK, that operate on a global telehealth platform and provide clinical consultations, interventions and monitoring services for patients diagnosed with cancer through the CareOncology Protocol (TREAT Program). CareOncology has also developed the AVRT program, which evaluates a patient’s potential risk of developing cancer and a variety of other chronic illnesses. AVRT provides monitoring/interventions that are intended to target the inflammatory and metabolic pathways that underlie the progression of many diseases.

In 2023 and the first and the second quarter of 2024, the Company focused on its CareOncology businesses and has also recently re-focused on the development and commercialization of Aristotle.

The Company is incorporated under the laws of the Province of Ontario and is domiciled in Ontario, Canada. Its shares are publicly traded under the stock symbol SZLS on the Toronto Stock Exchange. The Company’s registered office is located at Unit 30, 70 East Beaver Creek Road, Richmond Hill, Ontario, L4B 3B2.

StageZero Life Sciences Ltd. has wholly owned subsidiary companies, StageZero Holdings Inc., which owns 100% of StageZero Life Sciences Inc. (“Inc.”), Care Oncology, Inc, and SZ Physician Holdings, Inc, all in the United States, and Clinics Operations, Ltd. (also referred to as CareOncology UK).

These condensed consolidated interim financial statements have been prepared on a going concern basis, which assumes that the future operations will allow for the realization of assets and the discharge of liabilities in the normal course of business. These consolidated financial statements do not include any adjustments to the carrying value and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern, and such adjustments could be material. The Company reported a consolidated net loss of $0.6 million for the three months ended June 30, 2024 [June 2023 – loss of 0.4 million]. A loss of $1.0 million for the six-month period ended June 30, 2024 [2023 – loss of $2.2 million]. As at June 30, 2024, the Company had working capital deficit of $9.7 million [December 31, 2023, working capital deficit of $8.7 million] and a deficit of $127 million [December 31, 2023 – $126 million].

These circumstances create material uncertainties that cast significant doubt as to the ability of the Company to continue as a going concern and, hence, as to the appropriateness of the use of accounting principles applicable to a going concern. The Company is actively pursuing additional financing to further develop certain of the Company’s commercial and scientific initiatives; but there is no assurance these initiatives will be successful, timely or sufficient.

2. BASIS OF PRESENTATION

These consolidated financial statements have been prepared on a historical cost basis, except for the revaluation of certain financial instruments. The Company’s principal accounting policies outlined below have been applied consistently to all periods presented in these condensed consolidated interim financial statements.

7

STAGEZERO LIFE SCIENCES LTD. NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE SIX-MONTH PERIOD ENDED June 30, 2024 AND 2023 [EXPRESSED IN US DOLLARS]

Statement of compliance

These condensed consolidated interim financial statements have been prepared using accounting policies consistent with International Financial Reporting Standards (“IFRS”), and in accordance with International Accounting Standards (“IAS”) 34, Interim Financial Reporting, as issued by the International Accounting Standards Board (“IASB”). These condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2022 and the unaudited consolidated financial statements for the year ended December 31, 2023, which have been prepared in accordance with IFRS as issued by the IASB. The accounting policies followed in these condensed consolidated interim financial statements are consistent with those applied in the Company’s consolidated financial statements for the year ended December 31, 2022 and 2023. These condensed consolidated interim financial statements were approved and authorized for publication by the Board of Directors on September 26, 2024.

Accounting standards, amendments, and interpretations not yet adopted or effective

As discussed in the notes to the Company’s audited financial statements for the year ended December 31, 2023 certain new standards, amendments, and interpretations have been issued which are not yet effective for the Company’s consolidated financial statements for the periods presented. The Company has not early adopted any standards, amendments, or interpretations, which are issued but not yet effective.

3. ACQUISITION OF CARE ONCOLOGY BUSINESS

On September 2, 2021, the Company acquired 100% of the shares of Clinics Operations Limited (“COL”), a company incorporated in England and, through the Company’s newly incorporated subsidiaries, Care Oncology Inc.(“COI”) and Care Oncology Physicians (“COP”), the operating assets of Health Clinics USA Corp. Both were acquired from Health Clinics Limited (“HCL”), the ultimate parent of both entities, for consideration with a fair value of $7,283,827.

The consideration was comprised of: 12,500,000 shares issued on the date of closing, September 2, 2021; 2,500,000 shares that were issued upon the successful acquisition of a Care Quality Commission (“CQC”) license by COL (the “CQC Consideration”), October 22, 2021; and contingent consideration consisting of 8,000,000 common shares, pending approval by the Company’s shareholders. The 12,500,000 shares were valued based on the share price at issuance, September 2, 2021, being Cdn$ 0.42, or $4,160,625. These shares were subject to a Lock Up Agreement that restricted the Holders’ ability to sell those shares, releasing one third four months from the closing date, one third eight months from the closing date, and the final third on the anniversary of the closing date. On December 10, 2021 the shareholders elected to award the issuance of the 8,000,000 common shares upon achieving the Earn Out Consideration. Since the Earn Out Consideration revenue target was not attained in a continuous 12-month period between September 2021 and December 31, 2022, the 8,000,000 shares were not earned and are no longer due..

Company issued the additional 2,500,000 common shares on December 2, 2021, upon Clinic Operations Limited obtaining a Care Quality Commission license in England and accordingly, the related shares were valued using the same closing price, at $832,125.

4. INVENTORIES

Inventories comprise of lab supplies and test kits.

Inventory Impairment of inventory	At June 30, 2024 At December 31, 2023 22,570 22,570	At June 30, 2024 At December 31, 2023 22,570 22,570
	- -
Total Inventory
	22,570 22,570

8

STAGEZERO LIFE SCIENCES LTD. NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE SIX-MONTH PERIOD ENDED June 30, 2024 AND 2023 [EXPRESSED IN US DOLLARS]

5. TRADE AND OTHER PAYABLES

The Company’s exposure to liquidity and currency risks related to trade and other payables is presented in note 12.

	At June 30, 2024 At December 31, 2023 $ $	At June 30, 2024 At December 31, 2023 $ $
	3,875,694 3,811,586
Trade payables
Accrued directors' compensation	580,000 540,000
Accrued salary related expenses	3,208,172 2,783,255
Other accrued liabilities	1,096,486 716,840
Total trade payables and accrued liabilities	8,760,352 7,851,681

6. NOTES PAYABLE AND CONVERTIBLE DEBENTURES

Notes payable consists of:

	At June 30, 2024 At December 31, 2023 $ $	At June 30, 2024 At December 31, 2023 $ $
Note payable to HDL [a]	913,810 847,610 537,763 317,764
Note payable to shareholders and a director [b]
Total	1,451,573 1,165,374
Less: current portion of notes payable	(657,763) (437,764)
Long-term portion of notes payable	793,810 727,610

Convertible debenture held at fair value consists of:

	At June 30, 2024 At December 31, 2023	At June 30, 2024 At December 31, 2023	At June 30, 2024 At December 31, 2023	At June 30, 2024 At December 31, 2023
	$ $
Convertible debenture [c]	- 54,950
rm loans consist of:	At June 30, 2024 At December 31, 2023 $ $
Other loans [d] (short-term)	367,239 428,925
CEBA Loan [d] (long-term)	44,544 44,544

Term loans consist of:

9

STAGEZERO LIFE SCIENCES LTD. NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE SIX-MONTH PERIOD ENDED June 30, 2024 AND 2023 [EXPRESSED IN US DOLLARS]

[a] Note payable to HDL

In May 2015, StageZero Holdings issued a note payable in the amount of $1.0 million to Health Diagnostic Laboratories (HDL) to purchase additional shares of StageZero Life Sciences Inc. (formerly Innovative Diagnostic Lab) increasing its share from 33⅓% to 50% and in March 2016, StageZero Holdings assumed an additional $1.0 million note payable to HDL to own 100% of StageZero Life Sciences Inc. Effective March 1, 2017, the Company agreed to pay principal of $2,095,843.

On March 1, 2017 the Company and HDL’s representative reached an agreement pursuant to which StageZero Holdings would pay the principal amount of $2,095,843, to be paid in a $25,000 upfront payment and monthly payments of $15,000 beginning March 1, 2017 to July 1, 2017, followed by monthly payments of $10,000 until the outstanding debt has been paid in full.

The note payable was initially recognized at fair value, and subsequently measured at amortized cost using the effective interest rate method. The initial fair values were calculated with a valuation technique that uses parameters obtained from observable markets, including credit spread and interest rate volatility. The prevailing interest rate used in the valuations was 16% at initial recognition. The loan is unsecured, and the balance of the note is expected to be repaid in full by 2034. During six months ended June 30, 2024, the Company paid nil [2023 - nil]

[b] Notes payable to shareholders and director

At June 30, 2024, the convertible notes payable balance is $537,763 including accrued interest payable, which approximates the fair value. The notes are secured by a security interest in the Company’s patents and trademarks.

[c] Convertible debenture

Convertible Debenture Private Placement in August 2022

The Company closed a private placement of convertible debentures for gross proceeds of Cdn$177,000 in August, 2022 (the “Offering”). Each Unit is composed of (i) a $1,000 unsecured convertible debenture , bearing interest at a rate of 8% per annum, having a term of eighteen (18) months from the date of issuance and is convertible into common shares of the Company, at a conversion price of $0.11 per Common Share, and (ii) 9090 Common Share purchase warrants . Each Warrant is exercisable into one (1) Common Share of the Company at an exercise price of CAD$0.15 per Common Share for a period of eighteen (18) months from the date of issuance of the Units. Securities issued pursuant to the Offering are subject to a statutory hold period lasting four (4) months and a day after the issuance of the securities.

Fair value of convertible debenture

	$
At January 1, 2024		54,950
Issuance during the period		-
Revaluation during the period		-
Less: Conversion		54,950
At June 30, 2024		-

10

STAGEZERO LIFE SCIENCES LTD. NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE SIX-MONTH PERIOD ENDED June 30, 2024 AND 2023 [EXPRESSED IN US DOLLARS]

[d] Short-term and long-term loans

During 2020 and second quarter of 2021, the Company received a Cdn$60,000 Canada Emergency business Account (“CEBA”) loan from the Government of Canada via its commercial bank. The loan was interest free until January 18, 2024, with a maturity date of December 31, 2025. If Cdn$40,000 of the loan had been repaid by January 18, 2024, the remaining balance (maximum Cdn$20,000) would have been forgiven. Since the loan was not repaid by January 18, 2024, interest at 5% will be charged per annum until maturity on December 31, 2025. The loan is unsecured.

In 2023, the Company received a loan in the amount of $367,239 (2022 - $45,716) from a third party. The outstanding balance as at June 30, 2024 is $35,534. The loan from the third party is secured by a security interest in the Company’s accounts receivable.

7. WARRANT LIABILITY

	# $
At January 1, 2023	48,356,982 794,360
Warrant issued on April 13, 2023 Warrant issued on April 21, 2023 Warrant issued May 9, 2023	4,419,922 126,111 291,304 8,332 270,143 7,770 897,797 26,121 612,951 18,003 423,942 12,595 (215,354) - (14,622,744) -
Warrant issued on June 16, 2023
Warrant issued on July 12, 2023
Warrant issued on July 28, 2023
Warrant Exercised on July 13, 2023
Warrant expired during the year
Fair value changes	- (566,801)
At December 31, 2023	40,434,943 426,491
Warrant expired during the year	(7,862,554) -
Fair value changes	- (48,497)
At June 30, 2024	32,572,389 377,994

No warrants were issued during the first six months 2024 and above warrants are Long-term warrant liability.

The weighted average exercise price for total outstanding warrants as at June 30 2024 is Cdn$ 0.30. The exchange rate of USD to Cdn$ was 1.3687 at June 30, 2024.

Financial liability accounting

Because such warrants were denominated in Cdn$ [a currency different from the Company’s functional currency], they were recognized as a financial liability at fair value through profit or loss, except for broker warrants issued to Hampton Security Company, National Bank Financial Inc., Fidelity Clearing Canada ULC, and H.C. Wainwright & Co., LLC. which were compensation warrants and were recorded as contributed surplus in accordance with IFRS 2, Share-based Payments. The fair value of each warrant is estimated on the date of grant and on the valuation date using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires four subjective assumptions, including future stock price volatility of the Company’s common shares which trade on the TSX

11

STAGEZERO LIFE SCIENCES LTD. NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE SIX-MONTH PERIOD ENDED June 30, 2024 AND 2023 [EXPRESSED IN US DOLLARS]

(“Expected volatility”), the risk-free interest rate (sourced to Government of Canada Bond Yields for the noted term); expected dividend yield and expected time until exercise (“Expected life”), which greatly affect the calculated values.

The fair values of the warrants, except for broker warrants issued to Hampton Security Company, National Bank Financial Inc., Fidelity Clearing Canada ULC and H.C. Wainwright, was computed at June 30, 2024 using the BlackScholes option pricing model with the following assumptions (all with dividend yield of nil):

	Expiry date (mm/dd/yy)	Expected volatility	Risk-free interest rate	Expected life	Weighted- average fair value at measurement date
					(in Cdn$)
Date issued:
26-Nov-21 2-Mar-22 22-Nov-22 13-Apr-23	11/26/2025	141%	3.39%	1 years and 5 months 1 years and 8 months 2 years and 5 months 3 years and 10.5 months	0.00496 0.01287 0.02707 0.02867
	3/2/2026	141%	3.39%
	11/22/2027	141%	3.39%
	4/13/2028	141%	3.39%
21-Apr-23					0.02875
	4/21/2028	141%	3.39%	3 years and 10.5 months
9-May-23 16-Jun-23 12-Jul-23 28-Jul-23	5/9/2028 6/16/2028	141%			0.02894
			3.39%	3 years and 10 months
				3 years and 11.5 months 4 years and 0.5 months 4 years and 1 months
		141%	3.39%		0.02932 0.02957 0.02972
	7/12/2028	141%	3.39%
	7/28/2028	141%	3.39%

The exchange rate of USD to Cdn$ was Cdn$ 1.3687 at June 30, 2024.

8. SHARE CAPITAL

[a] Authorized

An unlimited number of non-voting preference shares, issuable in one or more series. Issued: none (2023: none). An unlimited number of voting special shares, entitling the holder to a dividend if and when declared by the Board in parity with the common shares and convertible into common shares. Issued: none (2023: none).

An unlimited number of voting common shares. Issued:123,532,948 common shares.

[b] Financings

Capital commitment agreement

On November 21, 2022, the Company announced that it had entered into a capital commitment agreement with GEM Global Yield Fund LLC SCS (“GEM”) for a Cdn$25 million Capital Commitment. Proceeds raised from the investment will be used for working capital and general corporate purposes, but especially to expand collaborations with employers, clinic and healthcare systems, and the insurers who support them. In December 2022, the Company issued 4,731,328 common shares and 4,731,328 warrants and received $206,004 (Cdn$280,000) under the agreement.

12

STAGEZERO LIFE SCIENCES LTD. NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE SIX-MONTH PERIOD ENDED June 30, 2024 AND 2023 [EXPRESSED IN US DOLLARS]

The commitment by GEM will provide funding up to CDN$25 million. The fee charged by GEM for the $25 million commitment is 2% or $500,000, which can be paid to them over the period that the funding is drawn down.

In 2023, the Company issued 4,711,226 common shares and 6,916,059 warrants and received $360,550 (Cdn$483,137) under the agreement.

[c] Weighted-average number of shares

On September 18, 2020 the Company announced that trading of the common shares on the TSX on a postConsolidation basis commenced at market opening on September 18, 2020. The Company’s options, warrants, including its TSX-listed warrants, and convertible debentures have also proportionately been adjusted in accordance with their terms effective September 18, 2020. All shares and purchase amounts in these consolidated financial statements have been retroactively restated to reflect the 1 for 8 consolidation. The weighted-average number of shares outstanding (post-consolidation) for period ended June 30, 2024, is 123,532,948 [December 31, 2023 – 123,532,948].

The Company has not adjusted its weighted-average number of shares outstanding for the purpose of calculating the diluted loss per share, as any adjustment would be antidilutive. All issued and outstanding stock options at June 30, 2024 of 14,514,219 [December 31, 2023 –14,514,219] and warrants of 32,572,389 (post-consolidation) [December 31, 2023 – 40,434,943] are deemed anti-dilutive such that the basic and net loss per share are equal.

[d] Employee stock option plan

On May 25, 2000, the Company adopted a stock option plan (the “Plan”) pursuant to which the Board may grant stock options to directors, officers, employees or consultants of the Company. The current terms of the Plan, approved by the Company’s shareholders on June 30, 2016, provide that the maximum number of common shares available for issuance under the Plan does not exceed 15% of the Company’s issued and outstanding shares at any time. All options granted have a term of five years from the date of grant. The vesting schedule of all granted options is determined at the discretion of the Board. The exercise price of an option must be not less than the closing price of the Company’s common shares on the TSX on the trading day immediately preceding the date the option is granted. As at June 30, 2024, there were 14,514,219 [December 31, 2023 –14,514,219] options outstanding, representing 12% [2023 – 12%] of the Company’s issued and outstanding common shares. All exercised options are settled by the issuance of the Company’s common shares.

There were no option cancellations or modifications to the Plan during the six-month periods ended June 30, 2024 and 2023.

In compliance with current accounting standards, the fair value of each stock option is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes model requires four subjective assumptions, including future stock price volatility and expected time until exercise, which greatly affect the calculated values. The following assumptions were used to calculate the weighted-average fair values of the stock options granted during the years ended:

ars ended:
	June 30, 2024 June 30, 2023
Expected option life in years	4.1 4.2
Expected volatility	149% 167%
Risk-free interest rate	3.34% 3.50%
Vesting period in years	0.5 0.5

13

STAGEZERO LIFE SCIENCES LTD. NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE SIX-MONTH PERIOD ENDED June 30, 2024 AND 2023 [EXPRESSED IN US DOLLARS]

The following table summarizes the measurement date weighted-average fair value of stock options granted during the periods ended June 30, 2024 and 2023:

Number of options granted #	Grant date weighted-average fair value
	(In Cdn$)
Six months ended June 30, 2024 - Six months ended June 30, 2023 6,717,000
	-
	0.065

The following is a summary of the status of the Plan at June 30, 2024 and 2023, and changes during the periods then ended:

ded:
		Six-month period ended June 30,
		2024	2023
	Number of options	Weighted-average	Number of options Weighted- average exercise price
		exercise price
	#	Cdn$	# Cdn$
Outstanding, beginning of period	14,514,219	0.315	6,865,524 0.638 8,436,712 0.065
Granted
	-	-
Exercised			(869,231) 0.065
	-	-
Expired or forfeited			(553,750) 0.638
	-	-
Outstanding, end of period	14,514,219	0.315	13,879,255 0.227
Exercisable, end of period	14,514,219	0.315	12,779,255 0.241

The following table summarizes information about stock options outstanding at June 30, 2024:

e following table summarizes information about stock options outstanding at June 30, 2024:	e following table summarizes information about stock options outstanding at June 30, 2024:	e following table summarizes information about stock options outstanding at June 30, 2024:	e following table summarizes information about stock options outstanding at June 30, 2024:	e following table summarizes information about stock options outstanding at June 30, 2024:
Year issued Year of expiry Range of exercise prices per share Number outstanding Number exercisable Weighted- average exercise price Weighted- average remaining contractual life
Cdn$ # # Cdn$ years

14

STAGEZERO LIFE SCIENCES LTD. NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE SIX-MONTH PERIOD ENDED June 30, 2024 AND 2023 [EXPRESSED IN US DOLLARS]

2019	2024	$0.80	1,862,399	1,862,399	$0.80	0.56
2017	2027	$1.52	9,375	9,375	$1.52	3.41
			14,514,219	14,514,219

9. EXPENSES BY NATURE

Expenses included in the consolidated statements of loss for six months period ended Juen30, 2024 and 2023, are as follows:

For six months period ended June 30,

	2024 2023
Direct costs $ Salaries and benefits 677,789 Share-based compensation - Rent and facilities - Depreciation - Professional fee - Public entity costs - Lab supplies and equipment maintenance - Officer equipment and maintenance - Shipping and courier - Other - Foreign exchange (gain) -	General and administrative Total Direct costs General and administrative $ $ $ $ 565,282 1,243,071 1,150,554 798,555 23,726 23,726 - 73,482 30,777 30,777 - 1,255 18,277 18,277 - 45,890 398,738 398,738 - 229,764 19,284 19,284 - 75,980 - -147,084 - 66,983 66,983 - 67,750 5,179 5,179 - 29,517 143,113 143,113 - 776,376 (46,256) (46,256)* - (1,994)	Total $ 1,949,109 73,482 1,255 45,890
		229,764
		75,980
		147,084 67,750 29,517 776,376 (1,994)
677,789	1,225,103 1,902,892 1,297,638 2,096,575	3,394,213

* Rent and facilities for lab and clinics were included into direct costs.

10. RELATED-PARTY TRANSACTIONS

The key management personnel of the Company at June 30, 2024 and 2023 are the directors, including the Chairman and Chief Executive Officer and the Interim CFO and Corporate Secretary.

15

STAGEZERO LIFE SCIENCES LTD. NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE SIX-MONTH PERIOD ENDED June 30, 2024 AND 2023 [EXPRESSED IN US DOLLARS]

Compensation for key management personnel of the Company is detailed below for six months ended June 30, 2024 and 2023:

nd 2023:
			Six Months Ended June 30
	Three Months Ended June 30
	2024	2023	2024 2023
	$	$	$ $
Salaries, fees and short-term benefits	97,500	97,500	195,000 195,000
Share-based compensation	-	-	- 200,295
	97,500	97,500	195,000 356,007

As at June 30, 2024, key management personnel controlled 11% (2023-2.0%) of the issued and outstanding common shares of the Company and $1,076,873 (2023-$708,400) of compensation remains unpaid to current and former key management personnel which is included in trade and other payables. Such amounts are unsecured, non-interest bearing with no fixed terms of repayment.

Stock options held by key management personnel to purchase common shares have the following expiry dates and exercise prices:

			Number outstanding	Number outstanding
Year issued	Year of expiry	Range of exercise prices per share	At June 30, 2024	At December 31, 2023
		$	#	#
2019	2024	0.8	1,371,357	1,371,357 1,187,500
2020	2025	0.44	1,187,500
2022	2027	0.15	2,740,000	2,740,000
2023				-
	2028	0.065	4,467,000
			9,765,857	5,298,857

11. SEGMENT INFORMATION

During the six months 2024,, management has re-focused on its operations respecting cancer testing and care. Consequently, the Company has one reportable operating segment, operating in two major geographic areas, North America and Western Europe.

12. FINANCIAL INSTRUMENTS AND FINANCIAL RISK-MANAGEMENT OBJECTIVES AND POLICIES

The Company is exposed to liquidity, credit and market risk, the management of which is overseen by the Company’s senior management.

16

STAGEZERO LIFE SCIENCES LTD. NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE SIX-MONTH PERIOD ENDED June 30, 2024 AND 2023 [EXPRESSED IN US DOLLARS]

The reader is cautioned that audited financial statements for the year ended December 31, 2023 have not been completed. Accordingly, changes to the opening balance sheet as at January 1, 2024 may necessitate changes to the financial statements for the six months period ended June 30, 2024.

[a] Financial instruments

The fair value of warrants is estimated using the Black-Scholes option pricing model incorporating various inputs including the underlying price volatility and discount rate, [see note 7 ]. All other notes payable were initially recognized at fair value, and subsequently were measured at amortized cost using the effective interest rate method, whereby the fair value of the notes payable approximates their carrying value. As at June 30, 2024, the Company’s warrant liability and notes payable, are carried on the consolidated statements of financial position at fair value, warrant liability has been classified as Level 2, and notes payable have been classified as Level 3, in the fair value hierarchy.

[b] Liquidity risk

Liquidity risk represents the contingency that the Company is unable to gather the funds required with respect to its financial obligations at the appropriate time and under reasonable conditions. The Company attempts to manage this risk in order to ensure that it has sufficient liquidity to be able to honour its current and future financial obligations under normal conditions and in exceptional circumstances. Financing strategies to ensure the management of this risk include resorting to the capital markets through the issuance of equity or debt securities.

The Company’s ability to continue as a going concern depends upon its ability to achieve profitable operations and raise additional capital. In the past three years, the Company has earned limited revenue. During 2024 and 2023, the Company completed a series of common share, structured notes payable, capital commitment, common share and warrant and convertible debenture financings. The Company expects to continue to pursue further financings as or until operations become profitable.

The tables below summarize the maturity profile of the Company’s financial instruments as at June 30, 2024 and December 31, 2023:

	1 year or less	1 to 5 years	5 years or more	Total
At June 30, 2024	$	$	$	$
Financial assets
Cash	20,721	-	-	20,721
Trade and other receivables	138,819	-	-	138,819
Financial liabilities
Trade and other payables	8,760,352	-	-	8,760,352
Notes payable	657,763	480,000	735,844	1,873,607
Short-term loans	367,239	-	-	367,239
Long-term loans	-	44,544	-	44,544
Short-term liabilities	67,340	-	-	67,340

17

STAGEZERO LIFE SCIENCES LTD. NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE SIX-MONTH PERIOD ENDED June 30, 2024 AND 2023 [EXPRESSED IN US DOLLARS]

==> picture [78 x 35] intentionally omitted <==

1 year or less 1 to 5 years At December 31, 2023 $ $	5 years or more Total $ $
Financial assets Cash 26,353 - Trade and other receivables 88,625 - Financial liabilities Trade and other payables 7,851,508 - Notes payable 437,764 480,000 Short-term loans 428,925 - Long-term loans - 44,544 Short-term liabilities 67,340 -	- 26,353 - 88,625 - 7,851,508 735,844 1,653,608 - 428,925 - 44,544 - 67,340

[c] Credit risk

The Company’s financial assets that are exposed to credit risk consist primarily of cash and other receivables.

[d] Market risk

Market risk is comprised of foreign exchange rate risk and interest rate risk.

Foreign exchange rate risk

The Company operates in Canada, the United States, and United Kingdom, and transacts business primarily with US partners and suppliers. During the six month period ended June 30, 2024, a 5% appreciation (depreciation) in the Cdn$ to US dollar foreign exchange rate, with all else being equal, would have affected net income by approximately $161,103 [December 31, 2023 – $168,258]; in the UK GBP to US dollar foreign exchange rate, with all else being equal, would have affected net income by approximately $14,506 [December 31, 2023 – $14,670].

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instruments will fluctuate because of changes in market interest rates.

13. CAPITAL RISK MANAGEMENT

The Company’s objective when managing capital is to safeguard its accumulated capital in order to maintain the ability to continue as a going concern and provide returns to shareholders and benefits to other stakeholders. The capital structure of the Company consists of issues of notes payable, common shares and warrants totaling $104.3 million as at June 30, 2024

18

STAGEZERO LIFE SCIENCES LTD. NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE SIX-MONTH PERIOD ENDED June 30, 2024 AND 2023 [EXPRESSED IN US DOLLARS]

To address this risk, the Company manages its capital structure and makes adjustments to it in light of economic conditions. Upon approval of the Board, the Company balances its overall capital structure through new share or debt issuances, or by undertaking other activities as deemed appropriate in the circumstances.

The Company is not subject to any capital requirements imposed by a lending institution or regulatory body, other than of the Toronto Stock Exchange (“TSX”) which requires adequate working capital or financial resources such that, in the opinion of TSX, it will be able to continue as a going concern.

The Company’s ability to continue as a going concern depends upon its ability to achieve profitable operations and raise additional capital. From 2019 to 2023, the Company completed a series of common share, structured notes payable, capital commitment, common share and warrant and convertible debenture financings.

14. FINANCE AND TRANSACTION COSTS

==> picture [187 x 34] intentionally omitted <==

Three-month period ended June 30 Six-month period ended June 30

	2024	2023 $	2024 2023 $ $
	$
Interest on note payable to HDL Interest on note payable to shareholder and director Interest on convertible debenture Interest costs on lease liability Other interest costs Total		30,603
	33,758		66,200 60,014
	4,717	-	8,960 3,042 2,210 7138
	0	-
	6,185	4,007	12,705 10,251
	8,008	65,270	3,343 159,276
	52,668	99,880	93,418 239,721

15. REVENUE

Revenue and deferred revenue:

Three-month period ended June 30 Six-month period ended June 30

	2024	2023	2024	2023
	$	$	$	$
Revenue	390,083	793,307	912,004	1,555,281
Deferred Revenue	37,208	8,171	37,208	16,746

19

STAGEZERO LIFE SCIENCES LTD. NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE SIX-MONTH PERIOD ENDED June 30, 2024 AND 2023 [EXPRESSED IN US DOLLARS]

16. COMMITMENTS AND CONTINGENCIES

From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business

20